Virginia M. Pierce
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Virginia M. Pierce has a total of 250 co-authors. Here are the top co-authors by number of shared publications:
- Melis N. Anahtar
Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
4 shared publications - Roby Paul Bhattacharyya
Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard
4 shared publications - Sarah E. Turbett
Massachusetts General Hospital
4 shared publications - Pardis C. Sabeti
Broad Institute of Massachusetts Institute of Technology and Harvard, Boston, Massachusetts, USA
3 shared publications - Abigail Manson McGuire
Infectious Disease and Microbiome Program, Broad Institute, Cambridge, Massachusetts, USA
2 shared publications Adrianne Gladden-Young
Broad Institute of Harvard and MIT, Cambridge, USA
2 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Cefepime versus piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa pneumonia
Background: Both piperacillin-tazobactam and cefepime are widely used for the treatment of pneumonia caused by Pseudomonas aeruginosa. Despite this, no studies have directly compared these agents for this purpose. Methods: We performed a single-center retrospective cohort study of patients with pneumonia caused by P. aeruginosa treated with piperacillin-tazobactam or cefepime. The co-primary outcomes were 30-day mortality and a 30-day desirability of outcome ranking (DOOR) incorporating clinical failure, resistance, acute kidney injury (AKI), and recurrence. Overlap-weighted (OW) analyses were used to account for confounding. Results: A total of 204 patients (piperacillin-tazobactam, n = 117; cefepime, n = 87) were included. Baseline characteristics were comparable between groups after OW. All-cause mortality occurred more frequently in patients who received piperacillin-tazobactam (23.1%) compared with those receiving cefepime (11.5%; p = 0.04, OW odds ratio 2.38, 95% CI 1.05–5.42). Conversely, no significant difference in the DOOR endpoint associated with receipt of piperacillin-tazobactam (46%, 95% CI 39% – 53%) was demonstrated. Rates of resistance development (12.0% vs 5.7%, p = 0.15; OW subhazard ratio 2.25, 95% CI 0.79–6.43), and clinical success (65% vs 70%; OW odds ratio 0.81, 95% CI 0.43–1.51) were similar amongst patients receiving piperacillin-tazobactam and cefepime, respectively. AKI incidence on study drug was likewise similar (7.0% vs 7.2%). Conclusion: In this comparative study of cefepime and piperacillin-tazobactam for P. aeruginosa pneumonia, increased risk of mortality was seen with piperacillin-tazobactam. No differences were seen in other key outcomes, although sample size limits interpretation. This finding warrants further investigation in larger studies.
- 2 September 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Open AccessCefepime versus piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa pneumonia
Background: Both piperacillin-tazobactam and cefepime are widely used for the treatment of pneumonia caused by Pseudomonas aeruginosa. Despite this, no studies have directly compared these agents for this purpose. Methods: We performed a single-center retrospective cohort study of patients with pneumonia caused by P. aeruginosa treated with piperacillin-tazobactam or cefepime. The co-primary outcomes were 30-day mortality and a 30-day desirability of outcome ranking (DOOR) incorporating clinical failure, resistance, acute kidney injury (AKI), and recurrence. Overlap-weighted (OW) analyses were used to account for confounding. Results: A total of 204 patients (piperacillin-tazobactam, n = 117; cefepime, n = 87) were included. Baseline characteristics were comparable between groups after OW. All-cause mortality occurred more frequently in patients who received piperacillin-tazobactam (23.1%) compared with those receiving cefepime (11.5%; p = 0.04, OW odds ratio 2.38, 95% CI 1.05–5.42). Conversely, no significant difference in the DOOR endpoint associated with receipt of piperacillin-tazobactam (46%, 95% CI 39% – 53%) was demonstrated. Rates of resistance development (12.0% vs 5.7%, p = 0.15; OW subhazard ratio 2.25, 95% CI 0.79–6.43), and clinical success (65% vs 70%; OW odds ratio 0.81, 95% CI 0.43–1.51) were similar amongst patients receiving piperacillin-tazobactam and cefepime, respectively. AKI incidence on study drug was likewise similar (7.0% vs 7.2%). Conclusion: In this comparative study of cefepime and piperacillin-tazobactam for P. aeruginosa pneumonia, increased risk of mortality was seen with piperacillin-tazobactam. No differences were seen in other key outcomes, although sample size limits interpretation. This finding warrants further investigation in larger studies.
- 18 November 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (1) , 44-48
First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa
We describe the first case of cefepime-zidebactam treatment-emergent resistance associated with clinical failure in a patient with Pseudomonas aeruginosa pneumonia. During treatment, cefepime-zidebactam minimum inhibitory concentrations increased from 8/8 to 32/32 mg/L. Whole-genome sequence analysis showed new mutations in the MexAB-OprM efflux operon that were associated with cross-resistance to ceftazidime-avibactam and imipenem-relebactam.
- 18 November 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (1) , 44-48
First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa
We describe the first case of cefepime-zidebactam treatment-emergent resistance associated with clinical failure in a patient with Pseudomonas aeruginosa pneumonia. During treatment, cefepime-zidebactam minimum inhibitory concentrations increased from 8/8 to 32/32 mg/L. Whole-genome sequence analysis showed new mutations in the MexAB-OprM efflux operon that were associated with cross-resistance to ceftazidime-avibactam and imipenem-relebactam.
- Open Access
- 12 November 2025
- Published by American Society for Microbiology in mBio
- Vol. 16 (11) , e0154025
The carbapenem inoculum effect provides insights into the molecular mechanisms underlying carbapenem resistance in the Enterobacterales
Carbapenem-resistant Enterobacterales (CRE) are important pathogens that can develop resistance via multiple molecular mechanisms, including hydrolysis or reduced antibiotic influx. Identifying these mechanisms can improve pathogen surveillance, infection control, and patient care. We investigated, both phenomenologically and mechanistically, how resistance mechanisms influence the carbapenem inoculum effect (IE), a phenomenon where inoculum size affects antimicrobial susceptibility testing (AST). We demonstrated that any of seven different carbapenemases were sufficient to impart a meropenem IE when transformed into a laboratory strain of Escherichia coli . Across 106 clinical CRE isolates spanning 6 genera and 12 species, the carbapenem IE strictly depended on resistance mechanism: all 36 carbapenemase-producing CRE (CP-CRE) exhibited a clear IE, whereas 43 porin-deficient CRE displayed none. Twenty-seven isolates with both carbapenemase production and porin deficiency exhibited high-level resistance at all inocula and still displayed an IE, albeit smaller in magnitude than CP-CRE with intact porins. Mechanistically, we found that CP-CRE released carbapenemase activity into the culture supernatant to protect other cells, and this released activity markedly increased upon exposure to lethal antibiotic doses. Concerningly, 50% and 24% of CP-CRE isolates changed susceptibility classification to meropenem and ertapenem, respectively, across the allowable inoculum range in clinical testing guidelines. The meropenem IE and the ratio of ertapenem to meropenem minimal inhibitory concentration (MIC) at standard inoculum reliably identified CP-CRE. Understanding how resistance mechanisms affect AST could improve diagnosis and guide therapies for CRE infections. IMPORTANCE: Infections caused by carbapenem-resistant Enterobacterales (CRE) pose significant threats to patients and public health worldwide. Carbapenem resistance can occur through several molecular mechanisms, including enzymatic hydrolysis by carbapenemases and reduced influx via porin mutations. Identifying carbapenemase-producing isolates could enable tailored antibiotic selection to improve patient outcomes and infection control measures to prevent further carbapenemase transmission. In a large collection of CRE isolates, we found that only carbapenemase-producing CRE exhibited an inoculum effect, in which their measured resistance varies markedly with cell density, which risks misdiagnosis. Further, this inoculum effect occurred under conditions where bacteria released carbapenemases to the community upon exposure to antibiotics that resulted in cell death. Measuring this inoculum effect, or integrating other data from routine antimicrobial susceptibility testing, enhanced carbapenem resistance detection, paving the way for more effective strategies to combat this growing public health crisis.
- 12 November 2025
- Published by American Society for Microbiology in mBio
- Vol. 16 (11) , e0154025
Open AccessThe carbapenem inoculum effect provides insights into the molecular mechanisms underlying carbapenem resistance in the Enterobacterales
Carbapenem-resistant Enterobacterales (CRE) are important pathogens that can develop resistance via multiple molecular mechanisms, including hydrolysis or reduced antibiotic influx. Identifying these mechanisms can improve pathogen surveillance, infection control, and patient care. We investigated, both phenomenologically and mechanistically, how resistance mechanisms influence the carbapenem inoculum effect (IE), a phenomenon where inoculum size affects antimicrobial susceptibility testing (AST). We demonstrated that any of seven different carbapenemases were sufficient to impart a meropenem IE when transformed into a laboratory strain of Escherichia coli . Across 106 clinical CRE isolates spanning 6 genera and 12 species, the carbapenem IE strictly depended on resistance mechanism: all 36 carbapenemase-producing CRE (CP-CRE) exhibited a clear IE, whereas 43 porin-deficient CRE displayed none. Twenty-seven isolates with both carbapenemase production and porin deficiency exhibited high-level resistance at all inocula and still displayed an IE, albeit smaller in magnitude than CP-CRE with intact porins. Mechanistically, we found that CP-CRE released carbapenemase activity into the culture supernatant to protect other cells, and this released activity markedly increased upon exposure to lethal antibiotic doses. Concerningly, 50% and 24% of CP-CRE isolates changed susceptibility classification to meropenem and ertapenem, respectively, across the allowable inoculum range in clinical testing guidelines. The meropenem IE and the ratio of ertapenem to meropenem minimal inhibitory concentration (MIC) at standard inoculum reliably identified CP-CRE. Understanding how resistance mechanisms affect AST could improve diagnosis and guide therapies for CRE infections. IMPORTANCE: Infections caused by carbapenem-resistant Enterobacterales (CRE) pose significant threats to patients and public health worldwide. Carbapenem resistance can occur through several molecular mechanisms, including enzymatic hydrolysis by carbapenemases and reduced influx via porin mutations. Identifying carbapenemase-producing isolates could enable tailored antibiotic selection to improve patient outcomes and infection control measures to prevent further carbapenemase transmission. In a large collection of CRE isolates, we found that only carbapenemase-producing CRE exhibited an inoculum effect, in which their measured resistance varies markedly with cell density, which risks misdiagnosis. Further, this inoculum effect occurred under conditions where bacteria released carbapenemases to the community upon exposure to antibiotics that resulted in cell death. Measuring this inoculum effect, or integrating other data from routine antimicrobial susceptibility testing, enhanced carbapenem resistance detection, paving the way for more effective strategies to combat this growing public health crisis.
- 1 December 2024
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 3 (12)
False-Positive HIV Testing in a Chimeric Antigen Receptor T-Cell Recipient: A Case Report
- 1 December 2024
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 3 (12)
False-Positive HIV Testing in a Chimeric Antigen Receptor T-Cell Recipient: A Case Report
- 13 November 2024
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 62 (11) , e0099724
Clinical pilot of bacterial transcriptional profiling as a combined genotypic and phenotypic antimicrobial susceptibility test
Antimicrobial resistance is a growing health threat, but standard methods for determining antibiotic susceptibility are slow and can delay optimal treatment, which is especially consequential in severe infections such as bacteremia. Novel approaches for rapid susceptibility profiling have emerged that characterize either bacterial response to antibiotics (phenotype) or detect specific resistance genes (genotype). G en o typic and Ph enotypic AST through R NA detection (GoPhAST-R) is a novel assay, performed directly on positive blood cultures, that integrates rapid transcriptional response profiling with the detection of key resistance gene transcripts, thereby providing simultaneous data on both phenotype and genotype. Here, we performed the first clinical pilot of GoPhAST-R on 42 positive blood cultures: 26 growing Escherichia coli , 15 growing Klebsiella pneumoniae , and 1 with both. An aliquot of each positive blood culture was exposed to nine different antibiotics, lysed, and underwent rapid transcriptional profiling on the NanoString platform; results were analyzed using an in-house susceptibility classification algorithm. GoPhAST-R achieved 95% overall agreement with standard antimicrobial susceptibility testing methods, with the highest agreement for beta-lactams (98%) and the lowest for fluoroquinolones (88%). Epidemic resistance genes including the extended spectrum beta-lactamase bla CTX-M-15 and the carbapenemase bla KPC were also detected within the population. This study demonstrates the clinical feasibility of using transcriptional response profiling for rapid resistance determination, although further validation with larger and more diverse bacterial populations will be essential in future work. GoPhAST-R represents a promising new approach for rapid and comprehensive antibiotic susceptibility testing in clinical settings. IMPORTANCE: Exposure to antibiotics causes differential transcriptional signatures in susceptible vs resistant bacteria. These differences can be leveraged to rapidly predict resistance profiles of Escherichia coli and Klebsiella pneumoniae in clinically positive blood cultures.
- 13 November 2024
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 62 (11) , e0099724
Clinical pilot of bacterial transcriptional profiling as a combined genotypic and phenotypic antimicrobial susceptibility test
Antimicrobial resistance is a growing health threat, but standard methods for determining antibiotic susceptibility are slow and can delay optimal treatment, which is especially consequential in severe infections such as bacteremia. Novel approaches for rapid susceptibility profiling have emerged that characterize either bacterial response to antibiotics (phenotype) or detect specific resistance genes (genotype). G en o typic and Ph enotypic AST through R NA detection (GoPhAST-R) is a novel assay, performed directly on positive blood cultures, that integrates rapid transcriptional response profiling with the detection of key resistance gene transcripts, thereby providing simultaneous data on both phenotype and genotype. Here, we performed the first clinical pilot of GoPhAST-R on 42 positive blood cultures: 26 growing Escherichia coli , 15 growing Klebsiella pneumoniae , and 1 with both. An aliquot of each positive blood culture was exposed to nine different antibiotics, lysed, and underwent rapid transcriptional profiling on the NanoString platform; results were analyzed using an in-house susceptibility classification algorithm. GoPhAST-R achieved 95% overall agreement with standard antimicrobial susceptibility testing methods, with the highest agreement for beta-lactams (98%) and the lowest for fluoroquinolones (88%). Epidemic resistance genes including the extended spectrum beta-lactamase bla CTX-M-15 and the carbapenemase bla KPC were also detected within the population. This study demonstrates the clinical feasibility of using transcriptional response profiling for rapid resistance determination, although further validation with larger and more diverse bacterial populations will be essential in future work. GoPhAST-R represents a promising new approach for rapid and comprehensive antibiotic susceptibility testing in clinical settings. IMPORTANCE: Exposure to antibiotics causes differential transcriptional signatures in susceptible vs resistant bacteria. These differences can be leveraged to rapidly predict resistance profiles of Escherichia coli and Klebsiella pneumoniae in clinically positive blood cultures.
- Open Access
- 1 October 2024
- Published by Royal Society of Chemistry (RSC) in Environmental Science: Water Research & Technology
- Vol. 11 (1) , 126-135
Respiratory human adenovirus outbreak captured in wastewater surveillance
Respiratory adenovirus wastewater surveillance was compared to clinical data from a 2022 outbreak, showing a correlation with cases. Respiratory adenoviruses were less prevalent, with types 40/41 dominating. The schematic illustrates findings.
- 1 October 2024
- Published by Royal Society of Chemistry (RSC) in Environmental Science: Water Research & Technology
- Vol. 11 (1) , 126-135
Open AccessRespiratory human adenovirus outbreak captured in wastewater surveillance
Respiratory adenovirus wastewater surveillance was compared to clinical data from a 2022 outbreak, showing a correlation with cases. Respiratory adenoviruses were less prevalent, with types 40/41 dominating. The schematic illustrates findings.
- Open Access
Clinical Pilot of Bacterial Transcriptional Profiling as a Combined Genotypic and Phenotypic Antimicrobial Susceptibility Test
Antimicrobial resistance is a growing health threat, but standard methods for determining antibiotic susceptibility are slow and can delay optimal treatment, which is especially consequential in severe infections such as bacteremia. Novel approaches for rapid susceptibility profiling have emerged that characterize either bacterial response to antibiotics (phenotype) or detect specific resistance genes (genotype). GoPhAST-R is a novel assay, performed directly on positive blood cultures, that integrates rapid transcriptional response profiling with detection of key resistance gene transcripts, thereby providing simultaneous data on both phenotype and genotype. Here, we performed the first clinical pilot of GoPhAST-R on 42 positive blood cultures: 26 growing Escherichia coli, 15 growing Klebsiella pneumoniae, and 1 with both. An aliquot of each positive blood culture was exposed to 9 different antibiotics, lysed, then underwent rapid transcriptional profiling on the NanoString® platform; results were analyzed using an in-house susceptibility classification algorithm. GoPhAST-R achieved 95% overall agreement with standard antimicrobial susceptibility testing methods, with the highest agreement for beta-lactams (98%) and the lowest for fluoroquinolones (88%). Epidemic resistance genes including the extended spectrum beta-lactamase bla CTX-M-15 and the carbapenemase bla KPC were also detected within the population. This study demonstrates the clinical feasibility of using transcriptional response profiling for rapid resistance determination, although further validation with larger and more diverse bacterial populations will be essential in future work. GoPhAST-R represents a promising new approach for rapid and comprehensive antibiotic susceptibility testing in clinical settings.
Open AccessClinical Pilot of Bacterial Transcriptional Profiling as a Combined Genotypic and Phenotypic Antimicrobial Susceptibility Test
Antimicrobial resistance is a growing health threat, but standard methods for determining antibiotic susceptibility are slow and can delay optimal treatment, which is especially consequential in severe infections such as bacteremia. Novel approaches for rapid susceptibility profiling have emerged that characterize either bacterial response to antibiotics (phenotype) or detect specific resistance genes (genotype). GoPhAST-R is a novel assay, performed directly on positive blood cultures, that integrates rapid transcriptional response profiling with detection of key resistance gene transcripts, thereby providing simultaneous data on both phenotype and genotype. Here, we performed the first clinical pilot of GoPhAST-R on 42 positive blood cultures: 26 growing Escherichia coli, 15 growing Klebsiella pneumoniae, and 1 with both. An aliquot of each positive blood culture was exposed to 9 different antibiotics, lysed, then underwent rapid transcriptional profiling on the NanoString® platform; results were analyzed using an in-house susceptibility classification algorithm. GoPhAST-R achieved 95% overall agreement with standard antimicrobial susceptibility testing methods, with the highest agreement for beta-lactams (98%) and the lowest for fluoroquinolones (88%). Epidemic resistance genes including the extended spectrum beta-lactamase bla CTX-M-15 and the carbapenemase bla KPC were also detected within the population. This study demonstrates the clinical feasibility of using transcriptional response profiling for rapid resistance determination, although further validation with larger and more diverse bacterial populations will be essential in future work. GoPhAST-R represents a promising new approach for rapid and comprehensive antibiotic susceptibility testing in clinical settings.
- Open Access
Respiratory human adenovirus outbreak captured in wastewater surveillance
Adenoviruses present challenges for traditional surveillance methods since there are more than 60 types that infect humans. Wastewater-based surveillance can supplement traditional surveillance methods for gastrointestinal-associated adenoviruses, but the ability to detect trends of respiratory-associated adenoviruses in wastewater remains unclear. We quantified human adenovirus type 4 (HAdV-4) in wastewater settled solids and compared wastewater measurements to clinical cases from an outbreak investigation beginning in late September 2023. The human adenovirus type 4 target was positively correlated with clinical cases (Spearman’s rho = 0.5470, p < 0.0001) and followed a similar trend during the outbreak. We also quantified human adenovirus types 3, 7, 14, 21, 40/41, and a pan-adenovirus assay that targets all types that infect humans. The respiratory adenoviruses comprised a small fraction of the adenoviruses in wastewater and types 40/41, which typically cause gastrointestinal disease, comprised the majority of the detected adenoviruses. The efficacy of adenovirus wastewater surveillance will depend on assay specificity and the public health action available for adenovirus types. WATER IMPACT STATEMENT Community adenovirus surveillance is strengthened by wastewater measurements. We evaluated the correlation between wastewater measurements and clinical cases during an outbreak of respiratory adenovirus type 4 infections on a college campus. Results indicate respiratory adenoviruses comprise a small portion of the adenoviruses measured in wastewater and the utility of adenovirus wastewater surveillance depends on the type and public health actionability.
Open AccessRespiratory human adenovirus outbreak captured in wastewater surveillance
Adenoviruses present challenges for traditional surveillance methods since there are more than 60 types that infect humans. Wastewater-based surveillance can supplement traditional surveillance methods for gastrointestinal-associated adenoviruses, but the ability to detect trends of respiratory-associated adenoviruses in wastewater remains unclear. We quantified human adenovirus type 4 (HAdV-4) in wastewater settled solids and compared wastewater measurements to clinical cases from an outbreak investigation beginning in late September 2023. The human adenovirus type 4 target was positively correlated with clinical cases (Spearman’s rho = 0.5470, p < 0.0001) and followed a similar trend during the outbreak. We also quantified human adenovirus types 3, 7, 14, 21, 40/41, and a pan-adenovirus assay that targets all types that infect humans. The respiratory adenoviruses comprised a small fraction of the adenoviruses in wastewater and types 40/41, which typically cause gastrointestinal disease, comprised the majority of the detected adenoviruses. The efficacy of adenovirus wastewater surveillance will depend on assay specificity and the public health action available for adenovirus types. WATER IMPACT STATEMENT Community adenovirus surveillance is strengthened by wastewater measurements. We evaluated the correlation between wastewater measurements and clinical cases during an outbreak of respiratory adenovirus type 4 infections on a college campus. Results indicate respiratory adenoviruses comprise a small portion of the adenoviruses measured in wastewater and the utility of adenovirus wastewater surveillance depends on the type and public health actionability.
- 4 April 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (5) , 1140-1147
How New Regulation of Laboratory-Developed Antimicrobial Susceptibility Tests Will Affect Infectious Diseases Clinical Practice
Antimicrobial resistance (AMR) affects 2.8 million Americans annually. AMR is identified through antimicrobial susceptibility testing (AST), but current and proposed regulatory policies from the United States Food and Drug Administration (FDA) jeopardize the future availability of AST for many microorganisms. Devices that perform AST must be cleared by the FDA using their susceptibility test interpretive criteria, also known as breakpoints. The FDA list of breakpoints is relatively short. Today, laboratories supplement FDA breakpoints using breakpoints published by the Clinical and Laboratory Standards Institute, using legacy devices and laboratory-developed tests (LDTs). FDA proposes to regulate LDTs, and with no FDA breakpoints for many drug–bug combinations, the risk is loss of AST for key clinical indications and stifling innovation in technology development. Effective solutions require collaboration between manufacturers, infectious diseases clinicians, pharmacists, laboratories, and the FDA.
- 4 April 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (5) , 1140-1147
How New Regulation of Laboratory-Developed Antimicrobial Susceptibility Tests Will Affect Infectious Diseases Clinical Practice
Antimicrobial resistance (AMR) affects 2.8 million Americans annually. AMR is identified through antimicrobial susceptibility testing (AST), but current and proposed regulatory policies from the United States Food and Drug Administration (FDA) jeopardize the future availability of AST for many microorganisms. Devices that perform AST must be cleared by the FDA using their susceptibility test interpretive criteria, also known as breakpoints. The FDA list of breakpoints is relatively short. Today, laboratories supplement FDA breakpoints using breakpoints published by the Clinical and Laboratory Standards Institute, using legacy devices and laboratory-developed tests (LDTs). FDA proposes to regulate LDTs, and with no FDA breakpoints for many drug–bug combinations, the risk is loss of AST for key clinical indications and stifling innovation in technology development. Effective solutions require collaboration between manufacturers, infectious diseases clinicians, pharmacists, laboratories, and the FDA.
- 1 February 2024
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 390 (5) , 482-484
Federal Oversight of Laboratory-Developed Tests
- 1 February 2024
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 390 (5) , 482-484
Federal Oversight of Laboratory-Developed Tests